On CB1s as an alternative to GLP-1s, with Punit Dhillon

CB1 inhibition is an approach that taps into the body’s natural metabolism to burn fat while preserving muscle for more sustainable weight loss. Unlike GLP-1s, which suppress appetite, CB1 inhibition activates fat-burning processes.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Punit Dhillon, CEO of Skye Bioscience, for a conversation on CB1 inhibitor antibodies in the obesity space.

Dhillon discusses GLP-1 weight-loss drugs like semaglutide having taken the world by storm, despite the concerns over side effects, as well as what CB1s could mean for the obesity and weight-loss field.

You can listen to episode 227 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.